Penn Medicine
Help | Search | Site Map | Contact   
faculty photo

Lynn Mara Schuchter, M.D.

C. Willard Robinson Professor of Hematology-Oncology
Attending Physician, Hospital of the University of Pennsylvania
Program Leader: Melanoma Program, Abramson Cancer Center of the University of Pennsylvania
Division Chief, Hematology-Oncology, University of Pennsylvania
Internal Advisory Board Member, University of Pennsylvania Center for Health Incentives and Behavioral Economics
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-131
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: 215-662-4859
Fax: 215-349-5866
Education:
B.S.
University of Michigan, 1978.
M.D.
Chicago Medical School, 1982.
Post-Graduate Training
Intern, Department of Medicine , Michael Reese Hospital, Chicago, IL, 1982-1983.
Resident, Department of Medicine, Michael Reese Hospital, Chicago, IL, 1983-1985.
Chief Medical Resident, Department of Medicine, Michael Reese Hospital, Chicago, IL, 1985-1986.
Clinical Fellow, Medical Oncology, The Johns Hopkins Oncology Center Baltimore, MD, 1986-1989.
Visiting Fellow, Biologic Response Modifier Program, NCI, Frederick, MD, 1987-1987.
Palliative Care Fellowship , Hospital of the University of Pennsylvania, Philadelphia,PA, 2016-present.
Certifications
American Board of Internal Medicine (Internal Medicine) , 1986.
American Board of Internal Medicine Subspecialty Certification in Medical Oncology, 1990.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Mochel MC, Ming ME, Imadojemu S, Gangadhar TC, Schuchter LM, Elenitsas R, Payne AS, Chu EY.: Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma. J Cutan Pathol. 43(9): 787-91, Sep 2016.

Dai J, Tetzlaff MT, Schuchter LM, Elder DE, Elenitsas R: Histopathologic and mutational analysis of a case of blue nevus-like melanoma. J Cutan Pathol. 43(9): 776-80, Sep 2016.

Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr, Lawrence DP, Logan TF, Schuchter LM, Nair S, Fecher L, Buchbinder EI, Berghorn E, Ruisi M, Kong G, Jiang J, Horak C, Hodi FS: Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 17(7): 943-55, July 2016.

Lu H, Liu S, Zhang G, Kwong LN, Zhu Y, Miller JP, Hu Y, Zhong W, Zeng J, Wu L, Krepler C, Sproesser K, Xiao M, Xu W, Karakousis GC, Schuchter LM, Field J, Zhang PJ, Herlyn M, Xu X, Guo W.: Oncogenic BRAF-Mediated Melanoma Cell Invasion. Cell Rep. 15(9): 2012-24, May 2016.

Shannan B, Chen Q, Watters A, Perego M, Krepler C, Thombre R, Li L, Rajan G, Peterson S, Gimotty PA, Wilson M, Nathanson KL, Gangadhar TC, Schuchter LM, Weeraratna AT, Herlyn M, Vultur A.: Enhancing the evaluation of PI3K inhibitors through 3D melanoma models. Pigment Cell Melanoma Res. 29(3), May 2016.

Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, Chae YC, Xu X, Choi H, Dimwamwa E, Ope O, Shannan B, Basu D, Zhang D, Guha M, Xiao M, Randell S, Sproesser K, Xu W, Liu J, Karakousis GC, Schuchter LM, Gangadhar TC, Amaravadi RK, Gu M, Xu C, Ghosh A, Xu W, Tian T, Zhang J, Zha S, Liu Q, Brafford P, Weeraratna A, Davies MA, Wargo JA, Avadhani NG, Lu Y, Mills GB, Altieri DC, Flaherty KT, Herlyn M.: Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest 126(5), May 2016.

Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, Chae YC, Xu X, Choi H, Dimwamwa E, Ope O, Shannan B, Basu D, Zhang D, Guha M, Xiao M, Randell S, Sproesser K, Xu W, Liu J, Karakousis GC, Schuchter LM, Gangadhar TC, Amaravadi RK, Gu M, Xu C, Ghosh A, Xu W, Tian T, Zhang J, Zha S, Liu Q, Brafford P, Weeraratna A, Davies MA, Wargo JA, Avadhani NG, Lu Y, Mills GB, Altieri DC, Flaherty KT, Herlyn M.: Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest. April 2016.

Krepler C, Xiao M, Sproesser K, Brafford PA, Shannan B, Beqiri M, Liu Q, Xu W, Garman B, Nathanson KL, Xu X, Karakousis GC, Mills GB, Lu Y, Ahmed TA, Poulikakos PI, Caponigro G, Boehm M, Peters M, Schuchter LM, Weeraratna AT, Herlyn M: Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clin Cancer Res. 22(7): 1592-602, April 2016.

Budina-Kolomets A, Webster MR, Leu JI, Jennis M, Krepler C, Guerrini A, Kossenkov AV, Xu W, Karakousis GC, Schuchter LM, Amaravadi RK, Wu H, Yin X, Liu Q, Lu Y, Mills GB, Xu X, George DL, Weeraratna AT, Murphy ME.: HSP70 inhibition limits FAK-dependent invasion and enhances the response to melanoma treatment with BRAF inhibitors. Cancer Res. March 2016.

Shannan B, Chen Q, Watters A, Perego M, Krepler C, Thombre R, Li L, Rajan G, Peterson S, Gimotty PA, Wilson M, Nathanson KL, Gangadhar TC, Schuchter LM, Weeraratna AT, Herlyn M, Vultur A.: Enhancing the evaluation of PI3K inhibitors through 3D melanoma models. Pigment Cell Melanoma Res. Feb 2016.

back to top
Last updated: 09/14/2016
The Trustees of the University of Pennsylvania
 
© The Trustees of the University of Pennsylvania. Site best viewed with Mozilla, NN, IE, or Safari.
SOM Home International Programs Penn Alumni Clinical Trials Centers and Institutes Departments Faculty Research Education Administration